{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:42:06Z","timestamp":1760280126179,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2192"],"award-info":[{"award-number":["2192"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA107399"],"award-info":[{"award-number":["P50 CA107399"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Therapy\u2010related myeloid neoplasms (t\u2010MN) are a leading cause of nonrelapse mortality after autologous peripheral blood stem cell transplantation (aPBSCT) in patients with Hodgkin lymphoma (HL) and non\u2010Hodgkin lymphomas (NHL). t\u2010MN patients treated at an earlier stage of disease evolution have a better prognosis, and this presents a need to identify patients at risk for t\u2010MN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a prospective longitudinal study design, this study evaluated peripheral blood parameters pre\u2010aPBSCT and on day 100, at 6 months, 1 year, 2 years, and 3 years in 304 patients treated with aPBSCT. The relation between peripheral blood parameters and subsequent development of t\u2010MN was examined, and nomograms were developed to identify patients at risk for t\u2010MN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010one patients developed t\u2010MN at a median of 1.95 years post\u2010aPBSCT. Hemoglobin, hematocrit, white blood cell, and platelet counts were lower among patients who developed t\u2010MN compared to those who did not; these differences appeared soon after aPBSCT, persisted, and preceded development of t\u2010MN. Older age at aPBSCT (hazard ratio [HR]<jats:sub>per_year_increase<\/jats:sub> = 1.08, <jats:italic>P<\/jats:italic> = .007), exposure to total body irradiation (TBI) (HR = 2.90, <jats:italic>P<\/jats:italic> = .04), and low 100\u2010day platelet count (HR<jats:sub>increase_per_unit_decline_in_PLT<\/jats:sub> = 1.01, <jats:italic>P<\/jats:italic> = .002) predicted subsequent t\u2010MN. These parameters and primary diagnosis allowed identification of patients at high risk of t\u2010MN (eg, an HL patient undergoing aPBSCT at the age of 70 years with TBI and with a day 100 PLT between 100,000 and 150,000 would have a 62% probability of developing t\u2010MN at 6 years post\u2010aPBSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Abnormalities in peripheral blood parameters can identify patients at high risk for t\u2010MN after aPBSCT for HL or NHL, allowing opportunities to personalize close surveillance and possible disease\u2010modifying interventions.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34072","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T11:59:52Z","timestamp":1640692792000},"page":"1392-1401","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peripheral blood parameter abnormalities precede therapy\u2010related myeloid neoplasms after autologous transplantation for lymphoma"],"prefix":"10.1002","volume":"128","author":[{"given":"Kimo","family":"Bachiashvili","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Department of Medicine University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liton","family":"Francisco","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alysia","family":"Bosworth","sequence":"additional","affiliation":[{"name":"Population Sciences City of Hope Duarte California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department of Medicine University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-5683","authenticated-orcid":false,"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama"},{"name":"Hematology\/Oncology Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0035"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3128"},{"key":"e_1_2_8_4_1","first-page":"1085","article-title":"Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia","volume":"84","author":"Witherspoon RP","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.963"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2578"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23966"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704124"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0673"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.330"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4496.412k14_4496_4503"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6712"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13968"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00547-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9791"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1261"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.947"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:09:34Z","timestamp":1760278174000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/cncr.34072"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34072","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"2021-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}